Neuromodulation Through Multisensory Stimulation for Visual Field Deficits in the Subacute
Homonymous visual field defects (HVFDs) after acquired brain injuries affect daily life by impairing reading, navigation, and social activities, often impacting anxiety and depression. Spontaneous recovery is rare. Rehabilitation approaches include restorative treatments, which aim to expand the visual field through th
| Condition(s) | Homonymous Hemianopsia, Stroke |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Homonymous visual field defects (HVFDs) after acquired brain injuries affect daily life by impairing reading, navigation, and social activities, often impacting anxiety and depression. Spontaneous recovery is rare. Rehabilitation approaches include restorative treatments, which aim to expand the visual field through the stimulation of the so-called transition zone, and compensatory strategies, such as audio-visual training (AVT), which combines eye movement exercises with synchronized visual and auditory cues to train oculomotor scanning and overcome the visual field loss. Combining AVT with non-invasive brain stimulation, such as transcranial direct current stimulation (tDCS), may enhance recovery by promoting brain plasticity. Early evidence suggests that tDCS applied to the lesioned vis |
| Who can participate | Inclusion Criteria: \- Presence of subacute acquired brain injury (\< 3 months) with HVFD according to Neurophthalmological evaluation Exclusion Criteria: * Presence of hemispatial neglect (indexed by pathological asymmetries on paper-and-pencil tests) * Disorders of conjugated eye movements * Other neurological disorders (e.g., dementia) * Exclusion criteria for brain stimulation (i.e., epilepsy or family history of epilepsy; implanted electrodes, stimulators, pacemakers, infusion pumps, or any implanted metal device; pregnancy) |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Istituto Auxologico Italiano |
| Locations | Milan, Lombardy, Italy |
| Start date | 2026-02-01 |
| NCT ID | NCT07358832 |
| Official listing | https://clinicaltrials.gov/study/NCT07358832 |